Literature DB >> 19899003

A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.

Darius Norkus1, Albert Miller, Juozas Kurtinaitis, Uwe Haverkamp, Sergey Popov, Franz-Josef Prott, Konstantinas Povilas Valuckas.   

Abstract

PURPOSE: To compare acute gastrointestinal (GI) and genitourinary (GU) toxicity between patient groups with localized prostate adenocarcinoma, treated with conventionally fractionated (CFRT) and hypofractionated (HFRT) three-dimensional conformal external-beam radiotherapy (3D-CRT). PATIENTS AND METHODS: 91 patients were enrolled into a randomized study with a minimum follow-up of 3 months. 44 men in the CFRT arm were irradiated with 74 Gy in 37 fractions at 2 Gy per fraction for 7.5 weeks. 47 men in the HFRT arm were treated with 57 Gy in 17 fractions for 3.5 weeks, given as 13 fractions of 3 Gy plus four fractions of 4.5 Gy. The clinical target volume (CTV) included the prostate and the base of seminal vesicles. The CTV-to-PTV (planning target volume) margin was 8-10 mm. Study patients had portal imaging and/or simulation performed on the first fractions and repeated at least weekly.
RESULTS: No acute grade 3 or 4 toxicities were observed. The grade 2 GU acute toxicity proportion was significantly lower in the HFRT arm: 19.1% versus 47.7% (chi(2)-test, p = 0.003). The grade 2 GU acute toxicity-free survival was significantly better in the HFRT arm (log-rank test, p = 0.008). The median duration of overall GI acute toxicity was shorter with HFRT: 3 compared to 6 weeks with CFRT (median test, p = 0.017).
CONCLUSION: In this first evaluation, the HFRT schedule is feasible and induces acceptable or even lower acute toxicity compared with the toxicities in the CFRT schedule. Extended follow-up is needed to justify this fractionation schedule's safety in the long term.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19899003     DOI: 10.1007/s00066-009-1982-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  21 in total

1.  Prostate cancer: biological dose considerations and constraints in tele- and brachytherapy.

Authors:  Wolfgang Dörr; Jana Jaal; Daniel Zips
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

2.  Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity.

Authors:  Guy Soete; Stefano Arcangeli; Gert De Meerleer; Valeria Landoni; Valerie Fonteyne; Giorgio Arcangeli; Wilfried De Neve; Guy Storme
Journal:  Radiother Oncol       Date:  2006-07-07       Impact factor: 6.280

3.  Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Authors:  Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

4.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

5.  Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.

Authors:  Berit L Madsen; R Alex Hsi; Huong T Pham; Jack F Fowler; Laura Esagui; John Corman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-15       Impact factor: 7.038

6.  Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.

Authors:  Eric E K Yeoh; Robert J Fraser; Roz E McGowan; Rochelle J Botten; Addolorata C Di Matteo; Daniel E Roos; Michael G Penniment; Martin F Borg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-03-15       Impact factor: 7.038

7.  Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.

Authors:  Kei Kitamura; Hiroki Shirato; Nobuo Shinohara; Toru Harabayashi; Rikiya Onimaru; Katsuhisa Fujita; Shinichi Shimizu; Katsuya Nonomura; Tomohiko Koyanagi; Kazuo Miyasaka
Journal:  Cancer J       Date:  2003 Jul-Aug       Impact factor: 3.360

8.  Transabdominal ultrasonography, computed tomography and electronic portal imaging for 3-dimensional conformal radiotherapy for prostate cancer.

Authors:  Barbara Alicja Jereczek-Fossa; Federica Cattani; Cristina Garibaldi; Dario Zerini; Raffaella Cambria; Genoveva Ionela Boboc; Marco Valenti; Anna Kowalczyk; Andrea Vavassori; Giovanni Battista Ivaldi; Mario Ciocca; Deliu Victor Matei; Ottavio De Cobelli; Roberto Orecchia
Journal:  Strahlenther Onkol       Date:  2007-11       Impact factor: 3.621

9.  Intra-fractional uncertainties in image-guided intensity-modulated radiotherapy (IMRT) of prostate cancer.

Authors:  Buelent Polat; Iris Guenther; Juergen Wilbert; Joachim Goebel; Reinhart A Sweeney; Michael Flentje; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2008-12-24       Impact factor: 3.621

10.  Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.

Authors:  Patrick A Kupelian; Twyla R Willoughby; Chandana A Reddy; Eric A Klein; Arul Mahadevan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-06-04       Impact factor: 7.038

View more
  18 in total

1.  Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.

Authors:  Matthias Guckenberger; Sami Ok; Bülent Polat; Reinhart A Sweeney; Michael Flentje
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

2.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

Authors:  Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler
Journal:  J Clin Oncol       Date:  2018-10-11       Impact factor: 44.544

3.  Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity.

Authors:  F Alongi; A Fogliata; P Navarria; A Tozzi; P Mancosu; F Lobefalo; G Reggiori; A Clivio; L Cozzi; M Scorsetti
Journal:  Strahlenther Onkol       Date:  2012-09-29       Impact factor: 3.621

Review 4.  Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.

Authors:  Thomas B Brunner; Cynthia L Eccles
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

5.  Radiation treatment for patients with intermediate-risk prostate cancer.

Authors:  David E Greene; Jyoti S Mayadev; Richard K Valicenti
Journal:  Ther Adv Urol       Date:  2012-06

6.  [External beam radiotherapy in the treatment of prostate cancer].

Authors:  D Böhmer
Journal:  Urologe A       Date:  2012-11       Impact factor: 0.639

7.  A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.

Authors:  Darius Norkus; Agata Karklelyte; Benedikt Engels; Harijati Versmessen; Romas Griskevicius; Mark De Ridder; Guy Storme; Eduardas Aleknavicius; Ernestas Janulionis; Konstantinas Povilas Valuckas
Journal:  Radiat Oncol       Date:  2013-09-04       Impact factor: 3.481

8.  Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis.

Authors:  Tobias Engel Ayer Botrel; Otávio Clark; Antônio Carlos Lima Pompeo; Francisco Flávio Horta Bretas; Marcus Vinicius Sadi; Ubirajara Ferreira; Rodolfo Borges Dos Reis
Journal:  Core Evid       Date:  2013-03-07

9.  Hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  L Chinsoo Cho; Robert Timmerman; Brian Kavanagh
Journal:  Prostate Cancer       Date:  2013-03-07

10.  Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis.

Authors:  Z Zhu; J Zhang; Y Liu; M Chen; P Guo; K Li
Journal:  Br J Cancer       Date:  2014-04-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.